Drugs / Aminohippurate Sodium

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) AMINOHIPPURATE SODIUM 1944-12-30 fda.gov

Trials 3 · a red edge is where a trial was stopped

194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05065372 Jul 2022 → Mar 2027 expected cardiovascular disorder, diabetic kidney disease, type 1 diabetes mellitus Kalie Tommerdahl Recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03584217 Oct 2018 → Jun 2023 diabetic kidney disease, obesity disorder, type 2 diabetes mellitus University of Colorado, Denver Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT01156220 Jan → Jun 2012 University Medical Center Hamburg-Eppendorf Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as aminohippurate sodium ClinicalTrials.gov intervention name — accepted as the source's own label NCT01156220
1

NCT05065372

Known as Aminohippurate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03584217
Known as Product name: Aminohipppurate Sodium "PAH" Product name: Aminohipppurate Sodium "PAH"NCT01156220
Modality Diagnostic / imaging agent “Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)” NCT03584217
Route Other “Injection, 500 mg, single dose over 5 min” NCT01156220